Dostarlimab: Review on success story and clinical trials

• Published in: Critical reviews in oncology/hematology 2024-06, Vol.198, p.104374, Article 104374
• Main Authors: Yadav, Rohitash, Mathur, Ishita, Haokip, Hoineiting Rebecca, Pandey, Avaneesh K., Kumar, Vinod, Jain, Neeraj
• Format: Article
• Language: English
• Subjects: Antibodies, Monoclonal, Humanized - therapeutic use; Checkpoint inhibitor; Clinical Trials as Topic; Dostarlimab; Endometrial cancer; Humans; Jemperli; Neoplasms - drug therapy; Neoplasms - immunology; Neoplasms - therapy; PD-1 inhibitor
• ISSN: 1040-8428; 1879-0461; 1879-0461
• DOI: 10.1016/j.critrevonc.2024.104374

The PD-1/PD-L1 pathway plays a significant role in inhibiting, escaping from immune response, and promoting self-tolerance of the tumour. Dostarlimab is a selective humanized monoclonal antibody designed to target PD-1 and block its activity with PD-L1, which further prevents the escape of tumour cells from immune surveillance. It got accelerated approval from the FDA for treating adults with mismatch repair deficient, recurrent, or advanced endometrial cancer, and studies confirmed its beneficial effects. A recently published clinical trial reported 100 % remission of advanced rectal cancer without significant side effects in the participants. This clinical trial is still going on and enrolling patients with different types of cancer, including ovarian cancer, melanoma, head and neck cancer, and breast cancer therapy. The clinical trial result gave hope and proof to the medical fraternity and patients for better treatment. The focus of this review is to summarise pre-clinical and clinical studies of Dostarlimab. [Display omitted] •Overview and Recent updates of ongoing trails of dostarlimab.•Dostarlimab therapeutic implications in cancer.•Current challenges and future treatment modalities of dostarlimab